Molecular Imaging

[1]  C. Rowe,et al.  The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias , 2008, Molecular Neurobiology.

[2]  Nelleke Tolboom,et al.  Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.

[3]  M. Olschewski,et al.  Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows In Vivo Detection of Thrombosis and Monitoring of Thrombolysis , 2008, Circulation.

[4]  Peter C M van Zijl,et al.  MR tracking of transplanted cells with “positive contrast” using manganese oxide nanoparticles , 2008, Magnetic resonance in medicine.

[5]  H. Soltanian-Zadeh,et al.  Effects of Ferumoxides – Protamine Sulfate Labeling on Immunomodulatory Characteristics of Macrophage-like THP-1 Cells , 2008, PloS one.

[6]  S. Neubauer,et al.  Visualization of Activated Platelets by Targeted Magnetic Resonance Imaging Utilizing Conformation-Specific Antibodies against Glycoprotein IIb/IIIa , 2008, Journal of Vascular Research.

[7]  C. Rowe,et al.  Aβ deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease , 2008, Neuropsychologia.

[8]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.

[9]  D. Kraitchman,et al.  Imaging of stem cells using MRI , 2008, Basic Research in Cardiology.

[10]  C. Bode,et al.  A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. , 2008, The Journal of clinical investigation.

[11]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[12]  Markus Schwaiger,et al.  Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.

[13]  S. Neubauer,et al.  Magnetic Resonance Imaging of Endothelial Adhesion Molecules in Mouse Atherosclerosis Using Dual-Targeted Microparticles of Iron Oxide , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Soltanian-Zadeh,et al.  Measurement of quantity of iron in magnetically labeled cells: comparison among different UV/VIS spectrometric methods. , 2007, BioTechniques.

[15]  Matthias Stuber,et al.  Positive contrast visualization of iron oxide‐labeled stem cells using inversion‐recovery with ON‐resonant water suppression (IRON) , 2007, Magnetic resonance in medicine.

[16]  Jurgen E Schneider,et al.  In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide , 2007, Nature Medicine.

[17]  M. Ramirez-Alvarado,et al.  In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques , 2007, Journal of neurochemistry.

[18]  D. Boturyn,et al.  In vivo optical imaging of integrin αV-β3 in mice using multivalent or monovalent cRGD targeting vectors , 2007, Molecular Cancer.

[19]  Phillip C Yang,et al.  In vitro comparison of the biological effects of three transfection methods for magnetically labeling mouse embryonic stem cells with ferumoxides , 2007, Magnetic resonance in medicine.

[20]  Samuel A Wickline,et al.  Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. , 2007, Ultrasound in medicine & biology.

[21]  S. DeKosky,et al.  Optimal time window for standardized uptake ratio as a simplified measure of PIB retension , 2007 .

[22]  B. Miller,et al.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.

[23]  Christopher C Rowe,et al.  Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease , 2007, Journal of Nuclear Medicine.

[24]  Wolfhard Semmler,et al.  Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.

[25]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[26]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[27]  H. Engler,et al.  In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  W. Heindel,et al.  In vivo imaging of integrin ανβ3 expression using fluorescence-mediated tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  B. Miller,et al.  Subtype of Mild Cognitive Impairment and Progression to Dementia and Death , 2006, Dementia and Geriatric Cognitive Disorders.

[30]  Hyuing Zhang,et al.  Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo , 2006, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[31]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[32]  A. Arbab,et al.  Expression of transferrin receptor and ferritin following ferumoxides–protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging , 2006, NMR in biomedicine.

[33]  Z. Fayad,et al.  Clearance of Iron Oxide Particles in Rat Liver: Effect of Hydrated Particle Size and Coating Material on Liver Metabolism , 2006, Investigative radiology.

[34]  Paul Edison,et al.  Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C‐PIB positron emission tomography study , 2006, Annals of neurology.

[35]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[36]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[37]  Kathryn Sharer,et al.  In vivo detection of single cells by MRI , 2006, Magnetic resonance in medicine.

[38]  Zahi A Fayad,et al.  Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): Sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T , 2006, Magnetic resonance in medicine.

[39]  Antony K. Chen,et al.  Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular Imaging , 2006, Annals of Biomedical Engineering.

[40]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[42]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[43]  A. Gee,et al.  Delineation of Positron Emission Tomography Imaging Agent Binding Sites on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.

[44]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  John M Pauly,et al.  Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles , 2005, Magnetic resonance in medicine.

[46]  A. Gee,et al.  Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.

[47]  Grace Hu,et al.  Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.

[48]  Ralph Weissleder,et al.  Molecular imaging in the clinical arena. , 2005, JAMA.

[49]  Alan P Koretsky,et al.  Sizing it up: Cellular MRI using micron‐sized iron oxide particles , 2005, Magnetic resonance in medicine.

[50]  Julie C Price,et al.  Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. , 2005, Archives of neurology.

[51]  René M. Botnar,et al.  Coronary magnetic resonance imaging: visualization of the vessel lumen and the vessel wall and molecular imaging of arteriothrombosis , 2005, European Radiology.

[52]  Jeff W M Bulte,et al.  Iron oxide MR contrast agents for molecular and cellular imaging , 2004, NMR in biomedicine.

[53]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[54]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[55]  Alan A. Wilson,et al.  A rapid one-step radiosynthesis of the β-amyloid imaging radiotracer N-methyl-[11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1) , 2004 .

[56]  Heather Kalish,et al.  Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. , 2004, Blood.

[57]  Ryan Park,et al.  Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide. , 2004, Molecular imaging.

[58]  Ralph Weissleder,et al.  Seeing Within: Molecular Imaging of the Cardiovascular System , 2004, Circulation research.

[59]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[60]  Susannah H Bloch,et al.  Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. , 2004, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.

[61]  Max A Viergever,et al.  Passive tracking exploiting local signal conservation: The white marker phenomenon , 2003, Magnetic resonance in medicine.

[62]  A. Kassner,et al.  Molecular Imaging of Angiogenesis in Nascent Vx-2 Rabbit Tumors Using a Novel ανβ3-targeted Nanoparticle and 1.5 Tesla Magnetic Resonance Imaging , 2003 .

[63]  Jonathan R. Lindner,et al.  Imaging Tumor Angiogenesis With Contrast Ultrasound and Microbubbles Targeted to &agr;v&bgr;3 , 2003 .

[64]  G. Perry,et al.  Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[66]  H. Vinters,et al.  Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. , 2002, Bioconjugate chemistry.

[67]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[68]  R Weissleder,et al.  Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. , 2001, Radiology.

[69]  W. Klunk,et al.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.

[70]  J.S. Karp,et al.  Application of the 3D row action maximum likelihood algorithm to clinical PET imaging , 1999, 1999 IEEE Nuclear Science Symposium. Conference Record. 1999 Nuclear Science Symposium and Medical Imaging Conference (Cat. No.99CH37019).

[71]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[72]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[73]  D. Mash,et al.  Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. , 1998, Journal of neuropathology and experimental neurology.

[74]  E. Maxwell,et al.  Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor. , 1997, The Journal of pharmacology and experimental therapeutics.

[75]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[76]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[77]  Arthur W. Toga,et al.  A Probabilistic Atlas of the Human Brain: Theory and Rationale for Its Development The International Consortium for Brain Mapping (ICBM) , 1995, NeuroImage.

[78]  D. Price,et al.  Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody , 1994, Journal of neuropathology and experimental neurology.

[79]  D E Kuhl,et al.  Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[80]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[81]  Karl J. Friston,et al.  Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[82]  T. Carlos,et al.  Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. , 1990, Blood.

[83]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[84]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[85]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[86]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[87]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.